Cephalon Inc – ‘8-K’ for 9/15/98 – EX-99.1

As of:  Wednesday, 9/23/98   ·   For:  9/15/98   ·   Accession #:  1036050-98-1628   ·   File #:  0-19119

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Form 8-K for Cephalon, Inc.                            4     11K 
 2: EX-99.1     Press Release Dated September 15, 1998                 1      8K 
 3: EX-99.2     Press Release Dated September 18, 1998                 2±    10K 

EX-99.1   —   Press Release Dated September 15, 1998

EX-99.1
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
Contact:       Jason Rubin               Liz Shanahan (Europe)                  
 Cephalon, Inc.                 Sante Communications
610-738-6302              011-44-1-71-379-7377    

FOR IMMEDIATE RELEASE                                                           
---------------------                                                           

Cephalon and Chiron Withdraw Application to 
Market Myotrophin in Europe 

West Chester, PA - September 15, 1998 - Cephalon, Inc. (NASDAQ: CEPH) 
announced today that Cephalon-Chiron B.V. has withdrawn its application to the  
European Medicines Evaluation Agency (EMEA) seeking clearance to market         
MYOTROPHIN (mecasermin) Injection in Europe for the treatment of amyotrophic    
lateral sclerosis (ALS or motor neuron disease).  This decision was based on    
difficulties in resolving issues raised by the Rapporteurs concerning the       
differences in response seen in the two pivotal studies, and whether a benefit  
measured by slowing disease progression, using a functional rating scale, is    
considered clinically relevant.                                                 

   "It is not possible to resolve these issues within the timeframe allotted
to the review process," stated Frank Baldino, Jr., Ph.D., Cephalon's president  
and chief executive officer.  "Until these important issues are resolved, we do 
not believe it is worthwhile to proceed further towards a decision on this      
application."                                                                   

Cephalon, Inc., headquartered in West Chester, PA, is an international
biopharmaceutical company dedicated to the discovery, development and marketing 
of products to treat neurological disorders and cancer.                         

  In addition to historical facts, this press release may contain forward-
looking statements that involve risks and uncertainties that could cause actual 
results to differ materially from those reflected in the forward-looking        
statements.  These statements are based on the company's current belief as to   
the possibility and timing of future events.  Actual results could differ       
materially from those reflected in the forward-looking statements.  Factors     
which could cause actual results to differ from the company's expectations      
include, without limitation, the nature of regulatory decisions, the pricing of 
competitive products, the impact of litigation, risks commonly associated with  
development and commercialization of drugs and other specific factors that could
cause the company's performance to differ from current expectations.  These     
risks are described in documents the company files with the SEC, such as the    
most recent reports on Form 8-K, Form 10-Q and/or Form 10-K.                    

NOTE:  Cephalon's press releases are posted on the Internet at the    
company's Web site at http://www.cephalon.com.  They are also available by fax  
-----------------------             
24 hours a day at no charge by calling PR Newswire's Company News On-Call at    
800-758-5804, extension 134563.                                                 

Dates Referenced Herein

This ‘8-K’ Filing		Date		Other Filings
Filed on:		9/23/98		None on these Dates
For Period End:		9/15/98
				List all Filings